Sigma receptor ligands: applications in inflammation and oncology.

Curr Opin Investig Drugs

Sanofi-Synthélabo Recherche, Department of immunology and Oncology, 371 rue du Pr J Blayac, 34182 Montpellier, France.

Published: November 2004

Sigma (sigma) receptors were initially proposed as a subtype of opiate receptors, and bind several psychoactive compounds. They are classified into sigma 1 (sigma1) and sigma 2 (sigma2) subtypes. The characterization of these subunits, and the discovery of new specific sigma receptor ligands, demonstrated that sigma receptors belong to a specific entity distinct from opiate receptors. Radioligand-binding data have recently demonstrated that the sigma1 subtype is related to a sterol isomerase, which is involved in the cholesterol biosynthesis pathway, and also to another protein of unknown function, SRBP2 (SR-31747 binding-protein 2), which shares a high homology with this enzyme. This complex group of proteins also binds molecules devoid of central effect, which demonstrate potent anti-inflammatory properties, and so are potentially useful in pathologies where pro-inflammatory cytokines are involved, particularly rheumatoid arthritis, Crohn's disease or psoriasis. In addition, the two sigma receptor subtypes and their two related proteins are also expressed on tumor cells, where they could be of prognostic relevance, and their ligands could potentially be used in the detection and targeting of tumors.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sigma receptor
12
sigma
8
receptor ligands
8
sigma receptors
8
opiate receptors
8
ligands applications
4
applications inflammation
4
inflammation oncology
4
oncology sigma
4
sigma sigma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!